Clinical Trial

Real-world Evaluation of Patient Outcomes and Experiences With Ribociclib Early Adopters.

Study acronym: REPOWER
Recruiting
View on ClinicalTrials.gov →
Summary
This non-interventional study (NIS) aims to evaluate effectiveness, persistence, treatment patterns, adverse events (AEs), and patient-reported experience (including adherence, treatment satisfaction, health-related quality of life \[HRQoL\], work productivity, and etc.), among HR+/HER2- stage II and III eBC patients treated with ribociclib + ET, and to evaluate AEs and patients-reported experience among HR+/HER2- stage II and III eBC patients treated with abemaciclib + ET, as per local label.
Protocol Amendment History 2 changes
notable Primary completion moved earlier: 2030-05-30 -> 2030-04-30 2026-07-14
minor Completion moved earlier: 2030-05-30 -> 2030-04-30 2026-07-14
Trial Details
NCT Number NCT07243002
Lead Sponsor Novartis Pharmaceuticals
Conditions Breast Cancer
Enrollment 3,000 participants
Start Date 2025-12-15
Primary Completion 2030-04-30 (estimated)
Study Completion 2030-04-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-13